Giant Cell Arteritis Clinical Trial
Official title:
Fluorine-18-fluorodeoxyglucose Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment - A Diagnostic Window of Opportunity?
Verified date | October 2016 |
Source | University of Aarhus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Giant cell arteritis (GCA) affects large and medium sized vessels. Large vessel-GCA (LV-GCA)
affecting aorta and/or its main branches is seen a) together with temporal arteritis
(AT-GCA), b) as isolated LV-GCA but also c) with polymyalgia rheumatica.
There is a risk of vision loss and cerebral thromboembolic events or great vessel injury in
GCA. With delayed or inadequate treatment mortality and morbidity increases. This highlights
the need of fast diagnosis and early treatment.
The cornerstone in the diagnosis of GCA is a positive temporal artery biopsy. Patients with
LV-GCA have more general, but less cephalic symptoms than patients with AT-GCA. Also, biopsy
from large vessels can rarely be done and only 50% have a positive temporal artery biopsy
(TAB). Hence, diagnosis often rely on imaging.
Fluorine-18-fluorodeoxyglucose positron-emission tomography (FDG PET)/CT has shown high
diagnostic sensitivity and specificity and is believed to be superior to other imaging
modalities in the diagnosis of LV-GCA . The impact of FDG PET/CT in the management of LV-GCA
has been evaluated and has shown to increase the diagnostic accuracy in a significant
proportion of patients. However, studies have indicated a lower sensitivity in steroid
treated patients.
The aim of this study, was to evaluate the effect of steroid treatment on large-vessel FDG
uptake in new-onset, treatment-naive LV-GCA by repetitive FDG PET/CT pre- and post
therapeutic. With insights into the diagnostic capabilities after treatment is initiated, the
possibility of timely treatment and confident diagnostic work up will improve.
Status | Completed |
Enrollment | 24 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: 1. Clinical suspicion of GCA; Cranial symptoms, new-onset extremity claudication or protracted constitutional symptoms (weight loss > 5 kilograms or fever >38C for > 3 weeks). 2. C reactive protein >15 mg/l or erythrocyte sedimentation rate >40 mm/h 3. FDG PET/CT verified LV-GCA (steroid-naive) defined by FDG uptake in the aortic wall and/or supra-aortic branches with FDG uptake score =3. Exclusion Criteria: 1. oral glucocorticoid treatment within the past month 2. subcutaneously, intramuscularly, intraarticularly or intravenously administered glucocorticoid within the past 2 months 3. treatment with DMARDs or other immunosuppressive therapy ongoing or within the past 3 months 4. ongoing treatment with interleukin2 5. any disease mimicking GCA, including - a) autoimmune diseases with possible aortitis; rheumatoid arthritis, Cogans syndrome, relapsing polychondritis, ankylosing spondylitis, systemic lupus erythematosus, Buerger's disease, Bechet's disease, inflammatory bowel disease - b) infections with possible aortitis: syphilis, known active current or history of recurrent tuberculosis, hepatitis or HIV - c) other large-vessel disease: sarcoidosis, neurofibromatosis, congenital coarctation, Marfans syndrome, Ehlers-Danlos syndrome, retroperitoneal fibrosis 6. body weight of >150 kg. 7. Previously diagnosed and treated for PMR or GCA |
Country | Name | City | State |
---|---|---|---|
Denmark | Department of Rheumatology | Aarhus |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus |
Denmark,
Fuchs M, Briel M, Daikeler T, Walker UA, Rasch H, Berg S, Ng QK, Raatz H, Jayne D, Kötter I, Blockmans D, Cid MC, Prieto-González S, Lamprecht P, Salvarani C, Karageorgaki Z, Watts R, Luqmani R, Müller-Brand J, Tyndall A, Walter MA. The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging. 2012 Feb;39(2):344-53. doi: 10.1007/s00259-011-1967-x. Epub 2011 Nov 10. — View Citation
Prieto-González S, Depetris M, García-Martínez A, Espígol-Frigolé G, Tavera-Bahillo I, Corbera-Bellata M, Planas-Rigol E, Alba MA, Hernández-Rodríguez J, Grau JM, Lomeña F, Cid MC. Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study. Ann Rheum Dis. 2014 Jul;73(7):1388-92. doi: 10.1136/annrheumdis-2013-204572. Epub 2014 Mar 24. — View Citation
Puppo C, Massollo M, Paparo F, Camellino D, Piccardo A, Shoushtari Zadeh Naseri M, Villavecchia G, Rollandi GA, Cimmino MA. Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography. Biomed Res Int. 2014;2014:574248. doi: 10.1155/2014/574248. Epub 2014 Sep 1. Review. — View Citation
Stellingwerff MD, Brouwer E, Lensen KJ, Rutgers A, Arends S, van der Geest KS, Glaudemans AW, Slart RH. Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis: Need for Standardization. Medicine (Baltimore). 2015 Sep;94(37):e1542. doi: 10.1097/MD.0000000000001542. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of large vessel-GCA patients with post-therapeutic FDG uptake consistent with a diagnosis of large vessel giant cell arteritis | Proportion of patients with PET positive large vessel vasculitis defined as vascular FDG uptake=3, semiquantitative assesment ad modum Meller | Assessed after intervention (3 or 10 days of treatment, respectively) | |
Secondary | Change in quantitive uptake values (SUV) | The steroid induced change in FDG uptake assessed by; change in maximum standardized uptake values (SUV) | From baseline to post-treatments scan (3 or 10 days of treatment, respectively) | |
Secondary | Change in quantitive uptake values (TBR) | The steroid induced change in FDG uptake assessed by; change in target to background ratio (TBR)= SUVmax(artery)/SUVmean(venous blood pool) | From baseline to post-treatments scan (3 or 10 days of treatment, respectively) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03812302 -
Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA)
|
Phase 2 | |
Recruiting |
NCT02257866 -
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
|
||
Recruiting |
NCT04888221 -
Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement
|
Phase 3 | |
Recruiting |
NCT05380453 -
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
|
Phase 3 | |
Recruiting |
NCT02333708 -
Study of Circulating Microparticles in Giant Cell Arteritis
|
||
Completed |
NCT01450137 -
Tocilizumab for Patients With Giant Cell Arteritis
|
Phase 2 | |
Completed |
NCT03827018 -
KPL-301 for Subjects With Giant Cell Arteritis
|
Phase 2 | |
Active, not recruiting |
NCT04519580 -
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
|
||
Recruiting |
NCT04239196 -
Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA
|
Phase 2 | |
Recruiting |
NCT06460142 -
Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
|
||
Completed |
NCT03202368 -
An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)
|
Phase 3 | |
Not yet recruiting |
NCT02523625 -
Giant Cell Arteritis: Improving Use of Ultrasound Evaluation
|
N/A | |
Completed |
NCT02190916 -
Vasculitis Illness Perception (VIP) Study
|
N/A | |
Recruiting |
NCT01241305 -
One-Time DNA Study for Vasculitis
|
||
Terminated |
NCT02531633 -
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
|
Phase 3 | |
Completed |
NCT03765424 -
Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
|
||
Completed |
NCT03409913 -
Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA
|
N/A | |
Completed |
NCT01910038 -
Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.
|
Phase 2 | |
Not yet recruiting |
NCT04012905 -
Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering
|
Phase 3 | |
Recruiting |
NCT06004154 -
Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim)
|